Extremwetter: Noch sterben mehr Menschen an Kälte science.orf.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from science.orf.at Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
VANCOUVER, BC, May 4, 2021 /PRNewswire/ - Mountain Valley MD (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) announced it has filed a novel cancer adjuvant patent related to breast cancer, metastatic melanoma, and lung carcinoma.
Mountain Valley MD is a biotech and life sciences company implementing patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology.
MVMD s core technology applied to the Ivermectin drug is unique in that it only uses excipients (substances formulated alongside the active ingredient) that are
currently approved by the FDA.
Concurrent with its novel cancer adjuvant patent, MVMD is beginning pre-clinical trials with third-party cancer Contract Research Organizations (CROs).
On March 11th,
the Janssen vaccine whose laboratories belong to the Johnson & Johnson company was approved. In addition to this, four more have been integrated from the plan managed by the European Commission. Previously, the first Pfizer / BioNtech had already reached its approval on December 21st, 2020. Then, the Moderna appeared on January 6th and the AstraZeneca on January 29th.
The four
vaccines are authorized for distribution subject to conditions of clinical trials carried out since their inception. In other words, they are intended for the same populations for which they have already been approved in advance, through said evaluations.
Vaccinate pregnant and lactating women?